Study identifier:D1699R00050
ClinicalTrials.gov identifier:NCT06336330
EudraCT identifier:N/A
CTIS identifier:N/A
Early treatment of heart failure: a non-interventional study program of patients with heart failure and initiated on dapagliflozin (EVOLUTION-HF DEallEF)
Heart Diseases
N/A
No
-
All
1000
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
HFpEF Adult patients with preserved ejection fraction (HFpEF; EF≥50%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure. | - |
HFmrEF Adult patients with mildly reduced ejection fraction (HFmrEF; EF 41-49%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure. | - |
HFrEF Adult patients with reduced ejection fraction (HFrEF; EF ≤40%) who receive treatment with dapagliflozin in accordance with the local dapagliflozin product label for symptomatic chronic heart failure. | - |